CRO Partnerships

Building Resilient Development Models: How Mid-Size Pharma Can Scale Without Losing Control

Brian Healey

IQVIA

Outsourcing

The Hidden Operational Costs of Multi-Vendor Outsourcing Models

Pharma's Almanac

Clinical Blinding

Blinding Reconsidered: Why Trial Integrity Depends on More Than a Checkbox

David Alvaro, Ph.D.

Pharma's Almanac

Digital Formulation

Digital and In Silico Transformation in Biologics Formulation

Tim Menzen, Ph.D.; Andrea Arsiccio, Ph.D.,

Coriolis Pharma

Mass Spectrometry

Growing Importance of Mass Spectrometry from Drug Discovery through Commercialization and Life Cycle Management

Stefan Lehnert, Ph.D.; Carsten Kroeger, Dr. rer. nat.

Coriolis Pharma

CRO

Right-Sized CRO Support for Right-Sized Sponsors

Alexander Fetkovsky; Roman Hrynchuk

SanaClis

Global Growth

Beyond Borders: A Disciplined Approach to Successful Global Expansion

Eric B. Lev

Ampersand Capital Partners

Clinical Sites

Understanding Sponsor Expectations: Navigating Market Dynamics from a Site Perspective

Victor Lopes

Trialmed

Rare Disease Equity

Advancing Equity in Rare Disease Trials: Global Realities, Local Solutions

Rose Blackburne, M.D., MBA; Radojica Savic, M.D.; Galina Nesterova, MD

PPD clinical research business of Thermo Fisher Scientific

Clinical Platforms

Why Clinical Trial Platforms Must Evolve from Tools to Strategy

Chris Driver

IQVIA

Marketing

What Biotech and Pharma Buyers Actually Care About and How to Market Accordingly

Emilee Kudla

Pharma's Almanac

Recruitment

Bringing Clinical Trial Enrollment to the Point of Diagnosis

Tim Rich; Matt Schwartz

PPD clinical research business of Thermo Fisher Scientific

Particle Analysis

Advancing Subvisible Particle Characterization with Artificial Intelligence

Daniel Weinbuch, Ph.D.

Coriolis Pharma

Manufacturing

Advanced Pharmaceutical Manufacturing Concepts Are Quickly Becoming Realities

Tonia Becker; RECONNEX 365

Nice Insight

Future Medicines

How Today’s Pharmaceutical Industry is Transforming to Support the Medicines of the Future

Tonia Becker; RECONNEX 365

Nice Insight

Developability

Streamlining Drug Development with Integrated In Silico and Laboratory Developability Assessments

Andrea Arsiccio, Ph.D.,; Eva Keilhauer, Ph.D.; Kristian Le Vay, Ph.D.

Coriolis Pharma

Large Molecule

Managing Pharmacovigilance Challenges for Biosimilars

Ivana Lisec, MPharm

PrimeVigilance

Particle ID

Leveraging Formulation Development Experience for Effective Particle Identification

Jörg Müller, Ph.D.

Coriolis Pharma